Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
Nanox Imaging Ltd. has announced an exclusive distribution agreement with Intec SRL for its Nanox.ARC system in Argentina. This collaboration aims to expand access to cost-effective 3D medical imaging technology in Argentina's private healthcare sector. The Nanox.ARC system offers 3D imaging at a lower cost and reduced radiation compared to traditional CT scans.
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
Nanox Imaging Ltd. has signed an exclusive distribution agreement with Intec SRL for its Nanox.ARC digital tomosynthesis system in Argentina. This partnership aims to expand access to cost-effective 3D medical imaging in Argentina's private healthcare sector. Intec SRL will handle marketing, distribution, installation, and support, contributing to Nanox's Latin American expansion strategy.
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
Nanox Imaging Ltd. has announced an exclusive distribution agreement with Intec SRL for its Nanox.ARC system in Argentina. This partnership aims to expand access to cost-effective 3D medical imaging solutions in Argentina's private healthcare sector. Intec SRL will handle marketing, distribution, installation, and support, facilitating broader availability of the Nanox.ARC system, pending regulatory approvals.
Nanox Expands its European Reach With New Distribution Partnership
Nanox Imaging Ltd. has expanded its European presence through a new strategic alliance with Adriamed d.o.o. Beograd, a medical device distributor in Southeast Europe. This collaboration aims to enhance access to cost-effective medical imaging solutions, specifically bringing the Nanox.ARC digital tomosynthesis system to healthcare providers in Serbia, Montenegro, and Bosnia and Herzegovina. Adriamed will be the exclusive partner for distribution, installation, and support of the Nanox.ARC in the region, leveraging their local expertise to broaden market penetration.
Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026
Nanox (Nasdaq: NNOX) announced it will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time at the European Congress of Radiology (ECR) in Vienna from March 4-8, 2026. The company will also present new AI solutions, including FDA-cleared and CE-marked solutions for cardiac, bone, and liver analysis, as well as new data from the ADOPT study regarding AI-enabled vertebral fracture identification. This marks a significant step in Nanox's European market expansion, aiming to make advanced medical imaging more accessible and affordable.
Nanox Imaging to Showcase Nanox.ARC and AI Solutions at ECR 2026 in Vienna
NANO-X IMAGING LTD (Nanox) will feature its Nanox.ARC digital tomosynthesis system for the first time in Europe at the European Congress of Radiology (ECR) from March 4-8, 2026, in Vienna. The company will conduct live demonstrations of the CE-marked and FDA-cleared Nanox.ARC, which offers cost-effective 3D imaging with reduced radiation, and present new clinical data on lung cancer screening. Nanox will also highlight its AI solutions for analyzing CT scans for chronic disease detection and introduce new AI solutions for aortic valve calcification and body composition measurement.
Nano-X Imaging Ltd. Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
Nano-X Imaging Ltd. has received FDA 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for its Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. This clearance allows for an additional 2D view generated from digital tomosynthesis scans, aiming to support radiologist evaluation while maintaining a smooth workflow. This is a significant step in Nanox's strategy to position its tomosynthesis systems as primary diagnostic solutions, enhancing access to innovative medical imaging.
FDA clearance lets Nanox systems give 3D, 2D views without extra radiation
Nanox (NNOX) has received FDA 510(k) clearance for its TAP2D image enhancement capability for Nanox.ARC and Nanox.ARC X tomosynthesis systems. This feature allows the generation of a clear 2D view from a single tomosynthesis scan without additional radiation exposure, integrating into existing workflows. The clearance is a pivotal step in Nanox's strategy to remove the "adjunct use" label in the U.S., aiming for standalone primary imaging, mirroring its CE Mark status in Europe.
FDA clears Nanox’s TAP2D enhancement for tomosynthesis systems By Investing.com
Nano-X Imaging Ltd (NASDAQ:NNOX) announced that the FDA has granted 510(k) clearance for TAP2D, a cloud-enabled image enhancement capability for its tomosynthesis systems. This new feature generates a 2D image from a tomosynthesis scan, offering radiologists both 3D and 2D views from a single scan without additional radiation. The clearance is a key step in Nanox's strategy to position its systems as primary diagnostic solutions in the U.S., similar to their use in Europe.
Nano-X Imaging Secures FDA 510(k) Clearance for TAP2D Image Enhancement on Nanox.ARC Systems
Nano-X Imaging has received FDA 510(k) clearance for TAP2D, a cloud-based image enhancement tool for its Nanox.ARC tomosynthesis systems. This technology allows for both 2D and 3D views from a single scan without additional radiation, aiming to advance Nanox's systems toward a primary diagnostic role in the U.S. Despite this regulatory milestone, financial analysts at Spark maintain a Neutral rating on NNOX stock due to ongoing financial challenges.
Nano-X wins FDA for image enhancement software (NNOX:NASDAQ)
Nano-X Imaging (NNOX) shares rose approximately 12% in premarket trading after receiving FDA clearance for a new cloud-enabled image enhancement functionality for its digital X-ray systems, Nanox.ARC and Nanox.ARC X. This clearance signifies an important advancement for the company's technology.
Nanox Imaging Ltd Receives FDA Clearance for TAP2D, Enhancing Tomosynthesis Systems for Improved Diagnostic Capabilities
Nanox Imaging Ltd. (NNOX) has received FDA 510(k) clearance for its new TAP2D image enhancement capability, allowing its Nanox.ARC and Nanox.ARC X digital tomosynthesis systems to generate both 3D and 2D images from a single scan without additional radiation. This clearance is a key step in positioning the systems as primary diagnostic tools in the U.S., similar to their status in Europe, and enhances diagnostic capabilities while maintaining workflow efficiency. The company plans to remotely deploy this software upgrade to existing installations, furthering its mission to expand access to affordable and innovative medical imaging solutions globally.
Nanox Imaging Ltd Receives FDA Clearance for TAP2D, Enhancing Tomosynthesis Systems for Improved Diagnostic Capabilities
Nanox Imaging Ltd. announced FDA 510(k) clearance for TAP2D, a new cloud-enabled image enhancement feature for its Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. This capability allows radiologists to obtain both 3D and 2D images from a single tomosynthesis scan without additional radiation, aiming to position Nanox systems as primary diagnostic tools in the U.S., similar to their European CE Mark status. The company plans to remotely deploy this software enhancement to existing systems, furthering its mission to improve access to innovative medical imaging solutions.
FDA clears Nanox’s TAP2D enhancement for tomosynthesis systems
The FDA has granted 510(k) clearance for Nanox’s TAP2D, a cloud-enabled image enhancement feature for its digital tomosynthesis systems. This new feature generates a 2D image from a tomosynthesis scan without additional radiation, aiming to position Nanox's systems as primary diagnostic tools in the U.S. The company faces financial challenges despite revenue growth, with the stock trading below its Fair Value according to InvestingPro.
Nano-X Imaging (NASDAQ:NNOX) Stock Price Down 5.9% - What's Next?
Nano-X Imaging (NASDAQ:NNOX) stock dropped 5.9% to $3.01 on Wednesday, driven by a significant EPS miss and increased trading volume. Despite the stock trading below its key moving averages and maintaining unprofitability, institutional investors like UBS and ARK have recently increased their positions, holding 21.5% of the shares. Analysts have a mixed but generally positive outlook, with a consensus "Buy" rating and an average price target of $8.50.
Nanox Expands Distribution of Nanox.ARC Imaging System to Western Balkans
Nano-X Imaging Ltd. (Nasdaq: NNOX) has partnered with medical device distributor Adriamed to distribute its Nanox.ARC digital tomosynthesis system across Serbia, Montenegro, and Bosnia and Herzegovina. Adriamed will serve as the exclusive regional partner, managing marketing, distribution, installation, and support, aiming to expand Nanox's commercial presence in the Western Balkans.
Nanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina
Nanox Imaging Ltd. has announced a new collaboration with Adriamed d.o.o. Beograd to distribute its Nanox.ARC digital tomosynthesis system in Serbia, Montenegro, and Bosnia and Herzegovina. This partnership aims to expand access to cost-effective 3D medical imaging technology in the Western Balkans, building on Nanox's recent European expansions. Adriamed will be the exclusive partner for marketing, distribution, installation, and support of the Nanox.ARC in the region.
Nanox Expands in Europe with New Nanox.ARC Distribution
Nanox Imaging Ltd. has announced a new collaboration with Adriamed d.o.o. Beograd to distribute its Nanox.ARC imaging system in Serbia, Montenegro, and Bosnia and Herzegovina. This partnership aims to expand access to cost-effective, advanced 3D imaging technology in Southeast Europe. This move follows other recent European collaborations, reinforcing Nanox's strategy to enhance diagnostic capabilities and patient care through regional partners.
Lower-cost 3D imaging to reach underserved Western Balkans via Nanox deal
Nanox (Nasdaq: NNOX) announced an exclusive distribution agreement with Adriamed to commercialize its Nanox.ARC digital tomosynthesis system in Serbia, Montenegro, and Bosnia and Herzegovina. This collaboration, following other European deals, aims to provide healthcare providers in the Western Balkans with access to lower-cost 3D imaging technology. Adriamed will lead marketing, distribution, installation, and support, expanding Nanox's reach in the European market.
Nano-X Imaging Adjourns Annual Shareholders’ Meeting by One Day for Lack of Quorum
Nano-X Imaging Ltd. (NNOX) adjourned its Annual General Meeting of Shareholders on December 22, 2025, due to a lack of quorum, rescheduling it for December 23, 2025. The medical imaging technology company, which develops advanced X-ray systems, faces a "Neutral" rating from TipRanks’ AI Analyst Spark, balancing growth potential with financial challenges. Analysts currently rate NNOX a Buy with a $7.00 price target.
Nano-X Imaging (NASDAQ:NNOX) Stock Price Up 0.6% - Should You Buy?
Nano-X Imaging (NASDAQ:NNOX) shares increased by 0.6% on Monday, trading at $3.24 with reduced volume. The stock trades below its 50 and 200-day moving averages and has a market capitalization of approximately $211.8 million. Analyst sentiment is mixed but leans positive, with a consensus "Buy" rating and an average price target of $8.50, despite the company reporting a quarterly loss and negative financial metrics.
Cantor Fitzgerald reiterates Overweight rating on Nano-X Imaging stock
Cantor Fitzgerald maintained its Overweight rating and $7.00 price target on Nano-X Imaging (NASDAQ:NNOX) following the Radiological Society of North America (RSNA) 2025 meeting. The firm expressed an "incrementally positive" outlook on Nano-X, highlighting the new Nanox ARC X system's reduced radiation and smaller footprint, as well as the potential of its integrated AI offering. These positive reassessments come despite a recent decline in NNOX shares and are bolstered by recent strategic developments like new acquisitions and distribution agreements.
Nanox Imaging (Nasdaq: NNOX) taps Althea France to roll out CE-marked Nanox.ARC
Nanox (Nasdaq: NNOX) has partnered with Althea France to distribute its CE-marked Nanox.ARC multi-source digital tomosynthesis system across France. Althea France will manage market introduction, sales, and service, leveraging its extensive relationships with French hospitals and clinics. This agreement marks Nanox's fourth European distribution deal, following partnerships in Greece, Romania, and the Czech Republic, and aims to expand access to affordable, high-quality medical imaging throughout France.
Nanox to Launch FDA-Cleared Nanox.ARC X at RSNA 2025
Nano-X Imaging Ltd. (Nanox) will launch its FDA-cleared Nanox.ARC X multi-source digital tomosynthesis system at the RSNA 2025 Annual Meeting. The system, cleared in April 2025, offers advanced 3D imaging at a lower cost and radiation dose than CT, bridging the gap between conventional X-rays and CT scans. Nanox will also showcase its expanding AI portfolio, including new standalone AI innovations for aortic valve calcification and body composition measurements, and a pulmonary nodule AI solution under development.
Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System
Nanox has partnered with Althea France, a major European medical technology services provider, to distribute its CE-marked Nanox.ARC system across the French healthcare sector. This collaboration marks Nanox's fourth European distribution agreement, following similar partnerships in Greece, Romania, and the Czech Republic. The Nanox.ARC is a multi-source digital tomosynthesis system cleared for commercialization in the EU, offering advanced 3D imaging capabilities at a lower cost than traditional systems.
Nanox signs distribution deal with Althea France for imaging system
Nanox Imaging Ltd has signed a distribution agreement with Althea France to introduce its CE-marked Nanox.ARC imaging system across the French healthcare sector. The collaboration marks Nanox's fourth European distribution deal and aims to leverage Althea's expertise to provide affordable diagnostic capabilities. Despite recent stock volatility, Nanox continues to expand its market presence and technological impact in healthcare, as evidenced by other recent strategic partnerships and acquisitions.
Nanox announces USD 15M RDO
NANO-X IMAGING LTD has announced a registered direct offering for 3,826,530 ordinary shares, expecting to generate gross proceeds of approximately $15 million. The closing is anticipated around November 25, 2025, with net proceeds allocated to working capital and general corporate purposes. This capital raise aims to strengthen the balance sheet, accelerate growth initiatives, and expand market presence for Nanox.
Nanox Reaches Agreement with Vaso Corporation to Acquire
Nanox (NASDAQ: NNOX) announced an agreement to acquire VasoHealthcare IT Inc. (VHC IT) from Vaso Corporation (OTCQX: VASO) for up to $800,000. This acquisition aims to accelerate the deployment of Nanox’s AI solutions for analyzing CT scans across U.S. healthcare facilities. The integration of VHC IT's implementation capabilities with Nanox.AI is expected to expedite adoption and reduce time-to-value for healthcare providers.
Nanox Imaging Ltd Announces $15 Million Registered Direct Offering of Ordinary Shares
NANO-X IMAGING LTD announced a registered direct offering of 3,826,530 ordinary shares to an institutional investor, expecting gross proceeds of approximately $15 million. The offering, set to close around November 25, 2025, aims to strengthen Nanox's balance sheet and fund growth initiatives, including technological advancements and market expansion. The company, focused on making medical imaging accessible, will use the net proceeds for working capital and general corporate purposes.
Nanox Announces $15 Million Registered Direct Offering of Common Stock
Nanox announced a registered direct offering of 3,826,530 ordinary shares to a single institutional investor, expecting gross proceeds of approximately $15 million. This capital raise aims to strengthen Nanox's balance sheet, accelerate growth initiatives, advance technologies, expand market presence, and enhance AI infrastructure as the company scales deployments and capabilities. The proceeds will be used for working capital and general corporate purposes, reinforcing Nanox's mission to make high-quality medical imaging more accessible globally.
Nanox Announces $15 Million Registered Direct Offering of Common Stock
Nanox (NNOX) has announced a registered direct offering of 3,826,530 ordinary shares to a single institutional investor, expecting to raise approximately $15 million in gross proceeds. The company plans to use these funds for working capital and general corporate purposes, including advancing technologies, expanding market presence, and enhancing its AI infrastructure. The closing of the offering is anticipated around November 25, 2025.
Nanox (Nasdaq: NNOX) signs agreement to buy VasoHealthcare IT for $800K over 2 years
Nanox (Nasdaq: NNOX) has agreed to acquire VasoHealthcare IT Inc. from Vaso (OTCQX: VASO) for up to $800,000, consisting of $200,000 cash at closing and up to $600,000 in performance-based earnouts over two years. This acquisition aims to accelerate the U.S. deployment of Nanox's AI imaging solutions by integrating VHC IT's implementation, systems integration, workflow optimization, data migration, user training, and nationwide go-live support. The deal is expected to enable faster adoption and reduce time-to-value for healthcare providers utilizing Nanox.AI’s FDA-cleared CT-scan AI tools.
D. Boral Capital Maintains Nano-X Imaging (NNOX) Buy Recommendation
D. Boral Capital has reaffirmed a "Buy" recommendation for Nano-X Imaging (NNOX) based on a report from Fintel. Analysts project an average one-year price target of $7.90 per share, indicating a potential upside of 127.81% from the recent closing price. The company is also expected to see significant annual revenue growth and has a bullish fund sentiment with an increasing institutional ownership.
Nanox Announces Third Quarter of 2025 Financial Results and Provides Business Update
Nanox reported its third-quarter 2025 financial results, generating $3.4 million in revenue, up from $3.0 million in Q3 2024. The company announced the acquisition of Vaso Healthcare IT, securing new commercial collaborations, and expanding into Europe, while also providing full-year 2026 revenue guidance of $35 million. Despite a net loss of $13.7 million, Nanox is on track to meet its year-end system deployment target, emphasizing progress in technology, AI infrastructure, and operational efficiency.
Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions
Nanox (NASDAQ: NNOX) announced an agreement to acquire VasoHealthcare IT Inc. (VHC IT) from Vaso Corporation (OTCQX: VASO) to accelerate the deployment of Nanox’s AI solutions across U.S. healthcare facilities. The acquisition, valued at up to $800,000, aims to integrate VHC IT’s operational infrastructure and customer relationships with Nanox.AI’s FDA-cleared AI solutions, facilitating faster adoption and reducing time-to-value for healthcare providers. This move is expected to enhance Nanox's ability to efficiently onboard new customers and expand its commercial presence in the U.S.
Nanox Announces Strategic Partnership with 3DR® Labs to Expand AI-Powered Imaging Solutions Across North America
Nanox (NASDAQ: NNOX) has formed a strategic reseller partnership with 3DR Labs, a major provider of medical image post-processing services, to expand the reach of its AI-powered imaging solutions across North America. This collaboration will enable 3DR Labs to offer Nanox.AI’s FDA-cleared solutions, including HealthCCSng (cardiac), HealthOST (bone), and HealthFLD (liver) to its network of over 1,800 hospitals and imaging centers. The partnership aims to support early disease detection and improve clinical outcomes by integrating AI tools into existing radiology workflows.
Radiologists employ Nanox’s lung cancer screening tech at Paris hospital
Nano-X Imaging Ltd (NASDAQ: NNOX) has deployed its Nanox.ARC medical imaging technology for lung cancer screening at a private hospital in Paris, France, in collaboration with Olympe Imagerie. This device uses 80% less radiation than standard low-dose CT scanners and has received both CE Mark certification and FDA clearance for general adult diagnostics. The partnership aims to evaluate the Nanox.ARC's potential in early lung abnormality detection, enhancing patient outcomes through reduced radiation exposure and detailed 3D imaging.
Nanox to Launch FDA-Cleared Nanox.ARC X and Present
Nanox will showcase its FDA-cleared Nanox.ARC X multi-source digital tomosynthesis system and new AI solutions at the RSNA 2025 Annual Meeting. The Nanox.ARC X, cleared in April 2025, provides advanced 3D imaging at a lower cost and radiation dose than CT. The company will also highlight new AI innovations for pulmonary nodule detection, aortic valve calcification, and body composition measurements.
Nanox Imaging Ltd to Announce Q3 2025 Financial Results on November 20, 2025
Nanox Imaging Ltd will release its Q3 2025 financial results on November 20, 2025, before market open, followed by a conference call with CEO Erez Meltzer and CFO Ran Daniel at 8:30 a.m. ET. The medical imaging technology company aims to advance preventive healthcare through affordable AI-powered solutions, including cost-effective imaging systems, AI algorithms for CT readings, a cloud-based data management platform, and a decentralized teleradiology marketplace. The announcement details potential positives such as transparency and leadership in innovative medical imaging, while also noting potential negatives like the lack of financial forecasts and perceived delays in reporting.
Nano-X Imaging (NASDAQ:NNOX) Has Debt But No Earnings; Should You Worry?
Nano-X Imaging (NASDAQ:NNOX) carries debt but is currently unprofitable, with reported revenue of US$12 million over 12 months, marking a 17% gain. Despite negative free cash outflow and an accounting loss, the company holds net cash of US$48.6 million, giving it liquidity to manage its operations. The article suggests that while the balance sheet appears healthy due to this net cash position, investors should consider future earnings and potential risks associated with unprofitable companies.
Nano-X Imaging: Still No Opportunity Here (NASDAQ:NNOX)
Nano-X Imaging Ltd.'s Q2 results significantly missed expectations across revenue, EPS, and adjusted EPS, with losses widening. Despite some revenue growth and regulatory progress, the company's core fundamentals are weak, and its cash burn rate is unsustainable without further capital. The author reiterates a Sell rating for NNOX due to persistent underperformance, high cash outflows, and dilution risk.
Nano-X Imaging: Still Too Early To Invest (NASDAQ:NNOX)
Nano-X Imaging Ltd. shows promise with its AI-driven Nanox.ARC technology but remains unprofitable with no clear path to profitability. The company faces heavy operating losses, insufficient cash runway, and negative gross margins, likely requiring capital raises within 12 months. Despite revenue growth, rising costs, especially in the AI segment, indicate poor returns on investment, making NNOX a risky investment to avoid or sell for now, though it should be kept on a watchlist for future improvements.
Nanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X
Nanox has received FDA 510(k) clearance for its new multi-source digital tomosynthesis system, Nanox.ARC X, allowing for general use in producing tomographic images across various indications. This enhanced system features a streamlined design, smaller footprint, and 'plug and play' installation, aiming to increase accessibility to advanced 3D imaging technology. Nanox plans to offer the Nanox.ARC X later this year, expanding its product portfolio and mission to improve early detection and treatment through affordable medical imaging.
Daniel Ran, CFO of Nano-X Imaging, buys $3650 in NNOX shares
This article reports a client-side exception encountered while loading content from Investing.com, indicating that the intended news about Daniel Ran, CFO of Nano-X Imaging, buying NNOX shares could not be displayed. The issue prevents access to the specific details of the insider transaction.
NANO-X IMAGING LTD - Ordinary Shares (NQ: NNOX
This article provides a list of recent headline news and press releases related to NANO-X IMAGING LTD (NNOX). The news covers topics such as radiology innovation, artificial intelligence, earnings, and stock analysis from various financial news providers. The stock's current performance shows a slight decrease.
Griffin Asset Management Inc. Has $605,000 Position in Nano-X Imaging Ltd. $NNOX
Griffin Asset Management Inc. reduced its stake in Nano-X Imaging Ltd. (NASDAQ:NNOX) by 36.1% during the second quarter, valuing its holding at $605,000. Other institutional investors have also modified their positions, with 21.49% of the stock owned by institutional investors and hedge funds. Nano-X Imaging's stock has been trading with a twelve-month low of $3.60 and a high of $11.00, and the company recently reported its quarterly earnings, missing consensus estimates.
Nano-X Imaging Second Quarter 2025 Earnings: Misses Expectations
Nano-X Imaging reported its second-quarter 2025 earnings, revealing that revenue and earnings per share both missed analyst expectations. The company's revenue increased by 13% from the prior year, reaching US$3.04 million, but its net loss widened by 8.4% to US$14.7 million. Despite the current misses, analysts forecast a strong revenue growth of 51% p.a. over the next three years for Nano-X Imaging, significantly higher than the 5.9% projected for the overall U.S. healthcare industry.
NNOX Stock Price and Chart — NASDAQ:NNOX
This article provides a detailed overview of NANO-X IMAGING LTD (NNOX) stock performance, financials, and company information. It includes key statistics, historical price movements, analyst ratings, and frequently asked questions about the company's stock.
We Think Some Shareholders May Hesitate To Increase Nano-X Imaging Ltd.'s (NASDAQ:NNOX) CEO Compensation
Shareholders of Nano-X Imaging Ltd. (NASDAQ:NNOX) may be reluctant to approve an increase in CEO Erez Meltzer's compensation at the upcoming AGM, given a 64% loss in shareholder value over the past three years despite modest EPS growth. Meltzer's total compensation for 2023 was US$1.5 million, a 50% decrease from the previous year, with a significant portion (58%) attributed to salary, which is higher than the industry average. The article suggests shareholders may use the AGM to raise concerns about executive remuneration and the company's performance.
Nanox Receives FDA Clearance for Upgraded Version of Advanced AI Cardiac Solution
NANO-X IMAGING LTD's subsidiary, Nanox.AI, has received FDA 510(k) clearance for HealthCCSng V2.0, an upgraded AI cardiac solution. This new version introduces additional "zero calcium" categorization and generates a numerical calcium score, enhancing the identification of patients at high risk of coronary artery disease. The solution utilizes routine CT scans to opportunistically detect coronary artery calcium, aiding in timely preventive care and improving collaboration between radiology and cardiology.
